Scenarios that move ICLR
ICON plc - Ordinary Shares
Scenarios that move ICLR: 11 analyses, 9 positive, 2 negative.
- · Syndax stock falls 16% as Phase II fibrosis study misses primary goal — ▼ · impact -6 · confidence low · horizon quarters
- · Roche reports positive Phase III eye drug data, FDA accepts BLA — ▲ · impact +13 · confidence low · horizon quarters
- · argenx meets primary endpoint in Phase II celiac disease study — ▲ · impact +10 · confidence low · horizon quarters
- · Vaxcyte prices concurrent stock, warrant and convertible note offerings — ▲ · impact +20 · confidence low · horizon quarters
- · Spyre Therapeutics prices $350 million public stock offering — ▲ · impact +13 · confidence medium · horizon quarters
- · Zealand Pharma reports positive survodutide Phase III weight loss results — ▲ · impact +24 · confidence low · horizon quarters
- · DBV Technologies files FDA BLA for VIASKIN Peanut patch — ▲ · impact +10 · confidence low · horizon quarters
- · ADARx Pharmaceuticals prices upsized $446.3 million initial public offering — ▲ · impact +9 · confidence low · horizon quarters
- · Satellos wins FDA IND clearance for Forazapadin in FSHD — ▲ · impact +50 · confidence low · horizon weeks
- · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▲ · impact +12 · confidence low · horizon quarters
- · Sion cuts workforce nearly half after CF study failure — ▼ · impact -6 · confidence low · horizon quarters